Stem cells train heart following heart attack

Following a heart attack, part of the heart tissue dies. It is still not possible to restore the scar tissue arising as a result of this. The majority of stem cell researchers attempt to make new heart muscle cells from stem cells.

Liesbeth Winter of the Leiden University Medical Center, however, was able to prove the concept of using the embryonic potential of adult human cells to train the heart: this cell therapy ensured that less tissue died and that the remaining heart cells functioned better.

The PhD student used the 'Epicardium Derived Cell' or EPDC. This cell plays a crucial role during embryonic heart development: the embryonic EPDCs provide cells for the connective tissue skeleton of the heart and for the walls of the coronary arteries. EPDCs also play an important role in the formation of a thick, compact heart muscle wall. Without EPDCs, the heart muscle would remain very thin and the embryo would die.

Human cells stimulate mouse cells

Winter used adult human EPDCs that she extracted from the atrium of the heart. She transplanted these cells to a mouse heart that had suffered an infarction. The mice receiving these cells retained a better heart function than mice without these cells, both in the short term and in the longer term of several weeks. The human cells also ensured that less mouse cells died off. Two weeks following cell transplantation, the treated hearts contained more blood vessels, the heart muscle cells exhibited an increased activity of DNA damage repair, and the wall was thicker where the infarct had occurred. These results suggest that EPDCs have an almost instant stimulating effect on the surrounding heart tissue following transplantation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis